ArticleAmerican journal of translational research2021

Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis.

Antonio Facciorusso et al.PubMed ↗Full text ↗

No numbers read from the abstract.